Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sells 16,402 shares

Roivant Sciences Ltd. (NASDAQ: ROIV – Get a rating) COO Eric Venker sold 16,402 shares of the company in a trade dated Thursday, June 23. The shares were sold at an average price of $4.34, for a total transaction of $71,184.68. Following the completion of the transaction, the COO now owns 1,116,590 shares of the company, valued at $4,846,000.60. The transaction was disclosed in a legal filing with the SEC, which is available via this hyperlink.

Eric Venker also recently made the following trade(s):

  • On Friday May 20, Eric Venker sold 136,421 Roivant Sciences shares. The shares were sold at an average price of $3.70, for a total transaction of $504,757.70.
  • On Monday April 25, Eric Venker sold 5,107 Roivant Sciences shares. The shares were sold at an average price of $3.84, for a total transaction of $19,610.88.
  • On Wednesday March 30, Eric Venker sold 19,336 Roivant Sciences shares. The shares were sold at an average price of $4.84, for a total transaction of $93,586.24.

ROIV was down $0.11 during Monday trading hours, hitting $4.68. 726,702 shares of the company were traded, against an average volume of 589,702. Roivant Sciences Ltd. has a 12-month low of $2.52 and a 12-month high of $16.76. The company has a 50-day moving average of $3.90 and a 200-day moving average of $5.48. The company has a debt ratio of 0.09, a current ratio of 14.23 and a quick ratio of 14.23.

(A d)

Most people are terrible at buying and selling stocks at the right time, but the TradeSmith app takes the emotion out of investing.

Our back test shows that the average investor would have made $97,347 more just by using the analysis software in the TradeSmith app.

Watch this FREE video.

A number of institutional investors and hedge funds have recently changed their positions in the stock. SB Investment Advisers UK Ltd. bought a new equity stake in Roivant Sciences in Q4, valued at approximately $1,001,706,000. American International Group Inc. purchased a new equity stake in Roivant Sciences in Q1 worth approximately $8,965,000. Eventide Asset Management LLC increased its position in shares of Roivant Sciences by 141.5% in the 1st quarter. Eventide Asset Management LLC now owns 1,690,300 shares of the company valued at $8,177,000 after purchasing an additional 990,300 shares in the last quarter. Suvretta Capital Management LLC purchased a new equity stake in Roivant Sciences in Q4 valued at approximately $6,870,000. Finally, Two Seas Capital LP increased its stake in Roivant Sciences shares by 159.4% in the 1st quarter. Two Seas Capital LP now owns 806,907 shares of the company valued at $3,986,000 after purchasing an additional 495,862 shares last quarter. 61.49% of the shares are currently held by hedge funds and other institutional investors.

ROIV has been the subject of a number of research analyst reports. SVB Leerink launched coverage on shares of Roivant Sciences in a research note on Monday, May 23. They issued an “outperform” rating and a $6.00 price target on the stock. Goldman Sachs Group cut its price target on shares of Roivant Sciences from $15.00 to $12.00 and set a “buy” rating on the stock in a Tuesday, May 24 research note. Finally, Cantor Fitzgerald launched coverage on Roivant Sciences shares in a research note on Friday, April 29. They issued an “overweight” rating and a price target of $15.00 on the stock. Eight investment analysts have rated the stock with a buy rating. Based on data from MarketBeat, the stock currently has a consensus Buy rating and a consensus price target of $11.86.

About Roivant Sciences (Get a rating)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops drugs. The Company is developing product candidates for the treatment of various therapeutics, including solid tumors, sickle cell disease, hypophosphatasia, oncological malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis severe, autoimmune warm hemolytic anemia, thyroid eye disease, sarcoidosis, and Staphylococcus aureus bacteremia.

Further reading

Insider buying and selling by quarter for Roivant Sciences (NASDAQ:ROIV)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Roivant Sciences right now?

Before you consider Roivant Sciences, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Roivant Sciences didn’t make the list.

While Roivant Sciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Comments are closed.